Trevena Inc (TRVN)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Carrie L. Bourdow
Employees:
40
955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK, PA 19087
6103548840

Trevena focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain.

Data derived from most recent annual or quarterly report
Market Cap 10.411 Million Shares Outstanding8.975 Million Avg 30-day Volume 7.776 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-4.7
Price to Revenue0.0 Debt to Equity1.3272 EBITDA-43.755 Million
Price to Book Value0.6614 Operating Margin0.0 Enterprise Value-7.244 Million
Current Ratio3.837 EPS Growth0.465 Quick Ratio3.421
1 Yr BETA 7.9434 52-week High/Low 4.7 / 0.15 Profit Margin0.0
Operating Cash Flow Growth18.4064 Altman Z-Score-23.27 Free Cash Flow to Firm -29.83 Million
Earnings Report2023-08-10
View SEC Filings from TRVN instead.

View recent insider trading info

Trevena Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding TRVN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TRVN

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-06 by SHIN BARRY
  • 4: filed on 2023-01-06 by DRAKE PATRICIA M.
  • 4: filed on 2023-01-06 by BOURDOW CARRIE L.
  • 4: filed on 2023-01-06 by DEMITRACK MARK
  • 4: filed on 2023-01-06 by YODER ROBERT T
  • 4: filed on 2022-12-20 by BOURDOW CARRIE L.
  • 4: filed on 2022-12-20 by SHIN BARRY
  • 4: filed on 2022-12-20 by YODER ROBERT T
  • 4: filed on 2022-12-20 by DEMITRACK MARK
  • 4: filed on 2022-12-06 by BOURDOW CARRIE L.

    • Events (8k)

  • 8-K: filed on 2023-05-30:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-08:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-21:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2023-03-30:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-30:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-13:
    Item 8.01: Other Events
  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-29:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BOURDOW CARRIE L. PRESIDENT & CEO

    • Officer
    • Director
    		 192,074 2023-01-06 3

    DEMITRACK MARK SVP, CHIEF MEDICAL OFFICER

    • Officer
    		 80,028 2023-01-06 3

    YODER ROBERT T SVP, CHIEF BUSINESS OFFICER

    • Officer
    		 46,412 2023-01-06 3

    SHIN BARRY SVP, CFO

    • Officer
    		 83,267 2023-01-06 5

    DRAKE PATRICIA M. SVP, CHIEF COMMERCIAL OFFICER

    • Officer
    		 36,674 2023-01-06 3

    DOUGHERTY MICHAEL R

    • Director
    		 100,000 2022-06-09 1

    MOULDER LEON O JR

    • Director
    		 100,000 2022-06-09 1

    NUNN JASON RALEIGH

    • Director
    		 100,000 2022-06-09 1

    YANNI BARBARA

    • Director
    		 100,000 2022-06-09 1

    PHILLIPS ANNE M.

    • Director
    		 100,000 2022-06-09 1

    BRAUNSTEIN SCOTT

    • Director
    		 100,000 2022-06-09 1

    JOHNSON MARVIN

    • Director
    		 100,000 2022-06-09 1

    APPLEBAUM SCOTT CLCO; SVP, REGULATORY AFFAIRS

    • Officer
    		 344,022 2021-02-10 0

    GOWEN MAXINE

    • Director
    		 0 2020-05-13 0

    MCHUGH JULIE

    • Director
    		 0 2020-05-13 0

    HAMILL JOHN P. VP FIN,PRINC FIN&ACCT OFFICER

    • Officer
    		 82,234 2019-05-31 0

    KOPPEL ADAM

    • Director
    		 0 2018-05-16 0

    HABIB YACOUB SVP, BUS DEV & CORP PLANNING

    • Officer
    		 0 2018-03-22 0

    LIMONGELLI JOHN M SR. VP,GENERAL COUNSEL & CAO

    • Officer
    		 0 2018-02-28 0

    CUCA ROBERTO SR. VP AND CFO

    • Officer
    		 0 2018-02-28 0

    GEOGHEGAN DAVID SR. VP, OPERATIONS

    • Officer
    		 0 2018-02-28 0

    VIOLIN JONATHAN SVP-SCIENTIFIC AFFAIRS & IR

    • Officer
    		 0 2018-02-28 0

    LARK MICHAEL W. SR. VP, RESEARCH & CSO

    • Officer
    		 0 2017-08-28 0

    SOERGEL DAVID SR. VP,CLINICAL DEV. & CMO

    • Officer
    		 0 2017-03-02 0

    NADER FRANCOIS

    • Director
    		 0 2015-05-20 0

    NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP

    NEA PARTNERS 12, LIMITED PARTNERSHIP

    NEA 12 GP, LLC

    BARRETT M JAMES

    BARRIS PETER J

    BASKETT FOREST

    DRANT RYAN D

    KERINS PATRICK J

    KOLLURI KRISHNA KITTU

    SANDELL SCOTT D

    • 10% Owner
    		 4,811,691 2014-12-10 0

    ALTA PARTNERS VIII, L.P.

    ALTA PARTNERS MANAGEMENT VIII, LLC

    CHAMPSI FARAH

    JANNEY DANIEL

    NOHRA GUY P

    • Director
    • 10% Owner
    		 4,390,262 2014-12-10 0

    DEEGAN ROSAMOND SR VP, BUS DEV & OPERATIONS

    • Officer
    		 31,105 2014-09-29 0

    POLARIS VENTURE MANAGEMENT CO. V, L.L.C.

    POLARIS VENTURE PARTNERS V, L.P.

    POLARIS VENTURE PARTNERS ENTREPRENEURS' FUND V, L.P.

    POLARIS VENTURE PARTNERS FOUNDERS' FUND V, L.P.

    POLARIS VENTURE PARTNERS SPECIAL FOUNDERS' FUND V, L.P.

    MCGUIRE TERRANCE

    FLINT JONATHAN A

    • 10% Owner
    		 3,769,280 2014-08-14 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    TREVENA INC TRVN 2023-05-31 22:15:04 UTC -69.7657 74.8257 350000
    TREVENA INC TRVN 2023-05-31 21:45:04 UTC -69.7657 74.8257 350000
    TREVENA INC TRVN 2023-05-31 21:15:03 UTC -69.7657 74.8257 350000
    TREVENA INC TRVN 2023-05-31 20:45:04 UTC -69.7657 74.8257 200000
    TREVENA INC TRVN 2023-05-31 20:15:06 UTC -69.7657 74.8257 200000
    TREVENA INC TRVN 2023-05-31 19:45:04 UTC -69.7657 74.8257 200000
    TREVENA INC TRVN 2023-05-31 19:15:21 UTC -69.7657 74.8257 200000
    TREVENA INC TRVN 2023-05-31 18:45:03 UTC -69.7657 74.8257 200000
    TREVENA INC TRVN 2023-05-31 18:15:04 UTC -69.7657 74.8257 200000
    TREVENA INC TRVN 2023-05-31 17:45:03 UTC -69.7657 74.8257 150000
    TREVENA INC TRVN 2023-05-31 17:15:05 UTC -69.7657 74.8257 150000
    TREVENA INC TRVN 2023-05-31 16:45:04 UTC -69.7557 74.8257 150000
    TREVENA INC TRVN 2023-05-31 16:15:04 UTC -69.7557 74.8257 150000
    TREVENA INC TRVN 2023-05-31 15:45:03 UTC -69.7557 74.8257 150000
    TREVENA INC TRVN 2023-05-31 15:15:04 UTC -69.7557 74.8257 150000
    TREVENA INC TRVN 2023-05-31 14:45:04 UTC -69.7557 74.8257 100000
    TREVENA INC TRVN 2023-05-31 14:15:03 UTC -69.7557 74.8257 150000
    TREVENA INC TRVN 2023-05-31 13:45:04 UTC -76.5245 81.5945 150000
    TREVENA INC TRVN 2023-05-31 13:15:04 UTC -76.5245 81.5945 150000
    TREVENA INC TRVN 2023-05-31 12:45:04 UTC -76.5245 81.5945 150000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments